{"id":"iv-procainamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Lupus-like syndrome"},{"rate":null,"effect":"Agranulocytosis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Proarrhythmic effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Procainamide inhibits fast inward sodium current in cardiac tissue, which decreases the rate of depolarization and slows conduction through the atria and ventricles. It also has anticholinergic properties and prolongs the action potential duration and refractory period, making it effective for suppressing both atrial and ventricular arrhythmias.","oneSentence":"Procainamide is a Class IA antiarrhythmic that blocks cardiac sodium channels and slows conduction velocity to suppress abnormal electrical activity in the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:41.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation and atrial flutter"},{"name":"Ventricular tachycardia"},{"name":"Premature ventricular contractions"},{"name":"Wolff-Parkinson-White syndrome with rapid conduction"}]},"trialDetails":[{"nctId":"NCT04485195","phase":"PHASE4","title":"RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-06-17","conditions":"Atrial Fibrillation","enrollment":350},{"nctId":"NCT04234906","phase":"PHASE4","title":"Prevention of Post-Operative Cardiac Arrhythmias","status":"UNKNOWN","sponsor":"Jeffrey Moak","startDate":"2023-01","conditions":"Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery","enrollment":870},{"nctId":"NCT00383799","phase":"PHASE4","title":"Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia","status":"TERMINATED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2005-09","conditions":"Ventricular Tachycardia, Wide QRS Tachycardia","enrollment":302},{"nctId":"NCT00702117","phase":"PHASE4","title":"Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-06","conditions":"Atrial Fibrillation, Tachycardia, Ventricular, Brugada Syndrome","enrollment":123}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"iv Procainamide","genericName":"iv Procainamide","companyName":"Hospital General Universitario Gregorio Marañon","companyId":"hospital-general-universitario-gregorio-mara-on","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Procainamide is a Class IA antiarrhythmic that blocks cardiac sodium channels and slows conduction velocity to suppress abnormal electrical activity in the heart. Used for Atrial fibrillation and atrial flutter, Ventricular tachycardia, Premature ventricular contractions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}